Gyre Therapeutics, Inc.
No trades
No trades
Compare with Gyre Therapeutics, Inc.
−0.19 USD
5.03 M USD
116.59 M USD
23.65 M
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Company info
Sector
Industry
CEO
Ying Luo
Website
Headquarters
San Diego
Founded
1997
IPO date
Apr 12, 2006
ISIN
US4037831033
CUSIP
403783103
FIGI
BBG000F88SY8
Identifiers
ISIN US4037831033
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The firm operates two distinct segments: Gyre Pharmaceuticals and Gyre. The Gyre Pharmaceuticals segment extends three major commercial drug products including ETUARY, Etorel, and Contiva as well as several product candidates in preclinical and clinical development. The Gyre segment consists of the development and commercialization of Hydronidone for the treatment of metabolic dysfunction-associated steatohepatitis associated liver fibrosis. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
The current price of GYRE is 6.69 USD — it has decreased by −0.59% in the past 24 hours. Watch Gyre Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Gyre Therapeutics, Inc. stocks are traded under the ticker GYRE.
GYRE stock has risen by 3.88% compared to the previous week, the month change is a 2.14% rise, over the last year Gyre Therapeutics, Inc. has showed a −14.45% decrease.
We've gathered analysts' opinions on Gyre Therapeutics, Inc. future price: according to them, GYRE price has a max estimate of 20.00 USD and a min estimate of 18.00 USD. Watch GYRE chart and read a more detailed Gyre Therapeutics, Inc. stock forecast: see what analysts think of Gyre Therapeutics, Inc. and suggest that you do with its stocks.
GYRE reached its all-time high on Mar 1, 2011 with the price of 47,927.89 USD, and its all-time low was 2.83 USD and was reached on Mar 20, 2023. View more price dynamics on GYRE chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
GYRE stock is 3.97% volatile and has beta coefficient of 1.27. Track Gyre Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Gyre Therapeutics, Inc. there?
Today Gyre Therapeutics, Inc. has the market capitalization of 709.37 M, it has decreased by −4.79% over the last week.
Yes, you can track Gyre Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Gyre Therapeutics, Inc. is going to release the next earnings report on Nov 18, 2026. Keep track of upcoming events with our Earnings Calendar.
GYRE earnings for the last quarter are −0.12 USD per share, whereas the estimation was −0.06 USD resulting in a −111.76% surprise. The estimated earnings for the next quarter are −0.12 USD per share. See more details about Gyre Therapeutics, Inc. earnings.
Gyre Therapeutics, Inc. revenue for the last quarter amounts to 29.11 M USD, despite the estimated figure of 26.49 M USD. In the next quarter, revenue is expected to reach 28.40 M USD.
GYRE net income for the last quarter is −10.61 M USD, while the quarter before that showed −8.69 M USD of net income which accounts for 0.00% change. Track more Gyre Therapeutics, Inc. financial stats to get the full picture.
Gyre Therapeutics, Inc. dividend yield was 0.00% in 2025, and payout ratio reached 0.00%. The year before the numbers were 0.00% and 0.00% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 15, 2026, the company has 625 employees. See our rating of the largest employees — is Gyre Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Gyre Therapeutics, Inc. EBITDA is −10.12 M USD, and current EBITDA margin is 12.02%. See more stats in Gyre Therapeutics, Inc. financial statements.
Like other stocks, GYRE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Gyre Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Gyre Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Gyre Therapeutics, Inc. stock shows the sell signal. See more of Gyre Therapeutics, Inc. technicals for a more comprehensive analysis.